The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

While a partner (United Therapeutics) launching a potentially competing product might seem negative, MannKind views it as a market expansion opportunity. This "growing the pie" effect means MannKind can maintain a large, stable royalty stream even with a smaller share of a much larger total market, assuaging investor concerns.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

GSK's $2.2 billion acquisition of Wrap Therapeutics for a Phase 2b food allergy antibody demonstrates a high-conviction strategy. Instead of a typical licensing deal with milestones and royalties, GSK chose full ownership, indicating immense confidence in the mid-stage asset and a desire to control its entire development and commercial future.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

Following its largest-ever acquisition, MannKind's CEO is deliberately pausing further M&A activity. Instead of being "always opportunistic," the company is prioritizing integration and successful launches to avoid distractions. This disciplined focus on execution is intended to build shareholder confidence before considering future acquisitions.

The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.